Katrina K. Bakken

Delineation of<i>MGMT</i>Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma

Shiv K. Gupta, Sani H. Kizilbash, Brett L. Carlson et al. · JNCI Journal of the National Cancer Institute · 2015 · 121 citations · Full text

Medicine, Oncology, Pharmacology +17

Efflux Transporters at the Blood-Brain Barrier Limit Delivery and Efficacy of Cyclin-Dependent Kinase 4/6 Inhibitor Palbociclib (PD-0332991) in an Orthotopic Brain Tumor Model

Karen E. Parrish, Jenny L. Pokorny, Rajendar K. Mittapalli et al. · Journal of Pharmacology and Experimental Therapeutics · 2015 · 97 citations · Full text

Medicine, Oncology, Pharmacology +17

The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood–Brain Barrier in Glioblastoma

Jenny L. Pokorny, David Calligaris, Shiv K. Gupta et al. · Clinical Cancer Research · 2015 · 89 citations

Medicine, Oncology, Pharmacology +17

Heterogeneous delivery across the blood-brain barrier limits the efficacy of an EGFR-targeting antibody drug conjugate in glioblastoma

Bianca M. Marin, Kendra A. Porath, Sonia Jain et al. · Neuro-Oncology · 2021 · 81 citations · Full text

Medicine, Oncology, Pharmacology +17

Discordant <i>In Vitro</i> and <i>In Vivo</i> Chemopotentiating Effects of the PARP Inhibitor Veliparib in Temozolomide-Sensitive versus -Resistant Glioblastoma Multiforme Xenografts

Shiv K. Gupta, Ann C. Mladek, Brett L. Carlson et al. · Clinical Cancer Research · 2014 · 77 citations

Medicine, Oncology, Pharmacology +17